Program
nacubactam
Also written as “RO7079901”, “co-administration of cefepime and nacubactam” and “co-administration of aztreonam and nacubactam”.
Its studies are mostly in Intraabdominal Infections · Pyelonephritis · Urinary Tract Infections · Gram-Negative Bacterial Infections · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 40 open or running | phase 1since Nov 21, 2016 | Nov 21, 2016 | none ahead |
| Meiji Seika Pharma | 30 open or running | phase 3since Mar 2, 2023 | May 7, 2014 | none ahead |
- Named in fosun pharma’s own pipeline as
OP0595 (beta-lactamase inhibitor)
, phase 3, as of Sep 21, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 7, 2014First study: phase 1 study in Bacterial InfectionsNew to Meiji Seika PharmaMeiji Seika Pharma · NCT02134834 · 40 enrolled · Australia
- Nov 21, 2016Hoffmann-La Roche's first studies: 2 phase 1 studiesNew to Hoffmann-La RocheHoffmann-La Roche · NCT02972255, NCT02975388
- May 31, 2017Phase 1 study in Urinary Tract InfectionsHoffmann-La Roche · NCT03174795 · 20 enrolled · United States, Hungary, Latvia and more
- Jun 7, 2017Phase 1 study in Gram-Negative Bacterial InfectionsHoffmann-La Roche · NCT03182504 · 21 enrolled · United States
- Mar 2, 2023Phase 3 study in Complicated Urinary Tract InfectionMeiji Seika Pharma · NCT05905055 · 126 enrolled · China, Croatia, Czechia and more
- Apr 25, 2023Phase 3 study in Complicated Urinary Tract InfectionMeiji Seika Pharma · NCT05887908 · 614 enrolled · Bulgaria, China, Czechia and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05887908Complicated Urinary Tract Infection · Bulgaria, China, Czechia and more | 3 | Completed | Meiji Seika Pharma | Nov 22, 2024 | 614 |
| NCT05905055Complicated Urinary Tract Infection · China, Croatia, Czechia and more | 3 | Completed | Meiji Seika Pharma | Sep 1, 2025 | 126 |
| NCT03182504Gram-Negative Bacterial Infections · United States | 1 | Completed | Hoffmann-La Roche | Aug 10, 2017 | 21 |
| NCT03174795Urinary Tract Infections · United States, Hungary, Latvia and more | 1 | Completed | Hoffmann-La Roche | Dec 4, 2017 | 20 |
| NCT02975388Renal Insufficiency · United States | 1 | Completed | Hoffmann-La Roche | Jul 6, 2017 | 29 |
| NCT02972255Healthy Volunteers · United States | 1 | Completed | Hoffmann-La Roche | Mar 24, 2017 | 46 |
| NCT02134834Bacterial Infections · Australia | 1 | Completed | Meiji Seika Pharma | Aug 2014 | 40 |
How it is read
Names in the registry
- “RO7079901”, 3 entries
- “co-administration of cefepime and nacubactam”, 2 entries
- “co-administration of aztreonam and nacubactam”, 2 entries
- “nacubactam”, 1 entry
- “OP0595”, 1 entry
Conditions, from the studies’ own filings
- Intraabdominal Infections, 1 study
- Pyelonephritis, 1 study
- Urinary Tract Infections, 1 study
- Gram-Negative Bacterial Infections, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.